NZ333586A - Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity - Google Patents

Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity

Info

Publication number
NZ333586A
NZ333586A NZ333586A NZ33358697A NZ333586A NZ 333586 A NZ333586 A NZ 333586A NZ 333586 A NZ333586 A NZ 333586A NZ 33358697 A NZ33358697 A NZ 33358697A NZ 333586 A NZ333586 A NZ 333586A
Authority
NZ
New Zealand
Prior art keywords
useful
treating obesity
sulfamate derivatives
anticonvulsant sulfamate
preferably topiramate
Prior art date
Application number
NZ333586A
Other languages
English (en)
Inventor
Richard P Shank
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ333586(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NZ333586A publication Critical patent/NZ333586A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
NZ333586A 1996-06-28 1997-06-23 Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity NZ333586A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2200496P 1996-06-28 1996-06-28
PCT/US1997/010953 WO1998000130A2 (en) 1996-06-28 1997-06-23 Anticonvulsant sulfamate derivatives useful in treating obesity

Publications (1)

Publication Number Publication Date
NZ333586A true NZ333586A (en) 2000-05-26

Family

ID=21807338

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333586A NZ333586A (en) 1996-06-28 1997-06-23 Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity

Country Status (23)

Country Link
US (1) US6071537A (cg-RX-API-DMAC7.html)
EP (1) EP0915697B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000514425A (cg-RX-API-DMAC7.html)
CN (1) CN1106193C (cg-RX-API-DMAC7.html)
AP (1) AP1285A (cg-RX-API-DMAC7.html)
AT (1) ATE224189T1 (cg-RX-API-DMAC7.html)
AU (1) AU732923B2 (cg-RX-API-DMAC7.html)
BR (1) BR9710994A (cg-RX-API-DMAC7.html)
CA (1) CA2258893C (cg-RX-API-DMAC7.html)
CZ (1) CZ293876B6 (cg-RX-API-DMAC7.html)
DE (1) DE69715631T2 (cg-RX-API-DMAC7.html)
DK (1) DK0915697T3 (cg-RX-API-DMAC7.html)
ES (1) ES2184127T3 (cg-RX-API-DMAC7.html)
HU (1) HU226775B1 (cg-RX-API-DMAC7.html)
IL (1) IL127715A (cg-RX-API-DMAC7.html)
NO (1) NO317754B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ333586A (cg-RX-API-DMAC7.html)
PT (1) PT915697E (cg-RX-API-DMAC7.html)
RU (1) RU2214241C2 (cg-RX-API-DMAC7.html)
SK (1) SK284305B6 (cg-RX-API-DMAC7.html)
UA (1) UA53655C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998000130A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA975772B (cg-RX-API-DMAC7.html)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
CN100548290C (zh) 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
CA2369091C (en) * 1999-04-08 2005-01-11 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
NZ514810A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering lipids
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
WO2000061140A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
JP4709392B2 (ja) * 1999-04-08 2011-06-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
MXPA03000136A (es) 2000-07-07 2004-09-13 Johnson & Johnson Derivados anticonvulsivos utiles para prevenir el desarrollo de la diabetes mellitus de tipo ii o del sindromex.
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
MXPA03003870A (es) * 2000-10-30 2004-08-12 Johnson & Johnson Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
MXPA05011557A (es) * 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
AU2005206139B2 (en) 2004-01-13 2009-02-26 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1794143B8 (en) * 2004-08-24 2008-12-24 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US8853263B2 (en) * 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4586916A (en) * 1985-01-30 1986-05-06 Consolidated Papers, Inc. Corrugated carton separator
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates

Also Published As

Publication number Publication date
WO1998000130A3 (en) 1998-02-12
ES2184127T3 (es) 2003-04-01
AP1285A (en) 2004-06-24
IL127715A (en) 2004-07-25
AU3957897A (en) 1998-01-21
NO986052L (no) 1999-02-23
RU2214241C2 (ru) 2003-10-20
DE69715631T2 (de) 2003-05-08
SK284305B6 (sk) 2005-01-03
NO986052D0 (no) 1998-12-22
NO317754B1 (no) 2004-12-13
CN1224352A (zh) 1999-07-28
AP9801429A0 (en) 1998-12-31
CZ293876B6 (cs) 2004-08-18
US6071537A (en) 2000-06-06
WO1998000130A2 (en) 1998-01-08
JP2000514425A (ja) 2000-10-31
HU226775B1 (en) 2009-09-28
EP0915697B1 (en) 2002-09-18
PT915697E (pt) 2003-02-28
CA2258893C (en) 2005-06-14
BR9710994A (pt) 2000-10-24
HK1018743A1 (en) 2000-01-07
UA53655C2 (uk) 2003-02-17
HUP0001192A2 (hu) 2000-11-28
CA2258893A1 (en) 1998-01-08
SK180598A3 (en) 2000-07-11
CN1106193C (zh) 2003-04-23
ZA975772B (en) 1998-12-28
CZ427898A3 (cs) 1999-08-11
AU732923B2 (en) 2001-05-03
IL127715A0 (en) 1999-10-28
DK0915697T3 (da) 2003-01-27
EP0915697A2 (en) 1999-05-19
DE69715631D1 (de) 2002-10-24
ATE224189T1 (de) 2002-10-15
HUP0001192A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
NZ333586A (en) Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity
HU9300003D0 (en) Method for purifying water
GB9607695D0 (en) Process for treating oil-bearing formation
GB2266550B (en) Plant for treating drill cuttings
ZA939402B (en) Treatment method for lignocellulosic biomass
ZA962491B (en) On premise water treatment method
DE69634756D1 (de) Neue xylanaseverbindung und verfahren zu deren herstellung
UA35645C2 (uk) Добриво та спосіб його виробництва
BG102015A (en) Azacycloalkane derivatives, their preparation and application in therapy
HUP9602332A2 (en) Method of preparing 4,6-dichloro pyrimides
FI971035A7 (fi) Biokonversioprosessi trans-hydroksisulfonin syntetisoimiseksi
HU9302060D0 (en) Utilization of 1,2,5-oxadiazole-2-oxide derivatives for treating disturbances of erection
FI920108A7 (fi) Menetelmä veteen suspendoidun pigmentin käsittelemiseksi samoin kuin p aperinvalmistusmenetelmä
EP0469443A3 (en) Method of treating waste
HU913540D0 (en) Process for the protection of plant cultivation by using triazolyl- or imidazolyl-methyl-allyl-alcoholes, and the new compounds used in the process
NO980371D0 (no) Framgangsmåte for framstilling av en lösning av N-metylmorfolin-N-oksid i vann
GB9622739D0 (en) Direct tendon to pile connection
FI961888A7 (fi) Menetelmä massanvalmistuksen prosessiveden puhdistamiseksi
IL123283A0 (en) Improved method of treating water
MX9603503A (es) Agente para tratamiento de agua y metodo para tratar el agua.
HU9201866D0 (en) Process for improving the efficiency of water supply economy, and for the partial reconstruction of soil nutritives
EP0452863A3 (en) Process for treating wastes from waste waters obtained from the production of dyes
HU9500321D0 (en) Process for the preparation of 2,2'-dimorpholino-diethylether by reducing, catalytic amination of diethyleneglycol by morpholine
HUT56654A (en) Vertical, inhibiting oil purifier for purifying transformer oil during operation, with fuller's earth
MX9407703A (es) METODO PARA EL TRATAMIENTO DEL CHOQUE PUTREFACTIVO UTILIZANDO TIMOSINAa1.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired